Sarafanov Andrey G, Makogonenko Evgeny M, Pechik Igor V, Radtke Klaus-Peter, Khrenov Alexey V, Ananyeva Natalya M, Strickland Dudley K, Saenko Evgueni L
Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA.
Biochemistry. 2006 Feb 14;45(6):1829-40. doi: 10.1021/bi0520380.
Regulation of the coagulation factor VIII (fVIII) level in circulation involves a hepatic receptor low-density lipoprotein receptor-related protein (LRP). One of two major LRP binding sites in fVIII is located within the A2 domain (A2), likely exposed within the fVIII complex with von Willebrand factor and contributing to regulation of fVIII via LRP. This work aimed to identify A2 residues forming its LRP-binding site, previously shown to involve residues 484-509. Isolated A2 was subjected to alanine-scanning mutagenesis followed by expression of a set of mutants in a baculovirus system. In competition and surface plasmon resonance assays, affinities of A2 mutants K466A, R471A, R484A, S488A, R489A, R490A, H497A, and K499A for LRP were found to be decreased by 2-4-fold. This correlated with 1.3-1.5-fold decreases in the degree of LRP-mediated internalization of the mutants in cell culture. Combining these mutations into pairs led to cumulative effects, i.e., 7-13-fold decrease in affinity for LRP and 1.6-2.2-fold decrease in the degree of LRP-mediated internalization in cell culture. We conclude that the residues mentioned above play a key role in formation of the A2 binding epitope for LRP. Experiments in mice revealed an approximately 4.5 times shorter half-life for A2 in the circulation in comparison with that of fVIII. The half-lives of A2 mutant R471A/R484A or A2 co-injected with receptor-associated protein, a classical ligand of LRP, were prolonged by approximately 1.9 and approximately 3.5 times, respectively, compared to that of A2. This further confirms the importance of the mutated residues for interaction of A2 with LRP and suggests the existence of an LRP-dependent mechanism for removing A2 as a product of dissociation of activated fVIII from the circulation.
循环中凝血因子VIII(fVIII)水平的调节涉及肝脏受体低密度脂蛋白受体相关蛋白(LRP)。fVIII中两个主要的LRP结合位点之一位于A2结构域(A2)内,可能在fVIII与血管性血友病因子形成的复合物中暴露,并通过LRP参与fVIII的调节。这项研究旨在确定形成其LRP结合位点的A2残基,此前已证明该位点涉及484 - 509位残基。将分离的A2进行丙氨酸扫描诱变,随后在杆状病毒系统中表达一组突变体。在竞争和表面等离子体共振分析中,发现A2突变体K466A、R471A、R484A、S488A、R489A、R490A、H497A和K499A与LRP的亲和力降低了2 - 4倍。这与细胞培养中这些突变体的LRP介导的内化程度降低1.3 - 1.5倍相关。将这些突变成对组合会产生累积效应,即在细胞培养中,对LRP的亲和力降低7 - 13倍,LRP介导的内化程度降低1.6 - 2.2倍。我们得出结论,上述残基在形成A2与LRP的结合表位中起关键作用。在小鼠身上进行的实验表明,与fVIII相比,A2在循环中的半衰期缩短了约4.5倍。与A2相比,A2突变体R471A/R484A或与LRP的经典配体受体相关蛋白共注射的A2的半衰期分别延长了约1.9倍和约3.5倍。这进一步证实了突变残基对于A2与LRP相互作用的重要性,并表明存在一种依赖LRP的机制来清除作为活化fVIII从循环中解离产物的A2。